Financial Center, November 25 – TJ Pharma (600488) announced that its subsidiary has received approval for a new specification of potassium chloride injection and has passed the consistency evaluation for generic drugs. The announcement indicated that the subsidiary in Hubei has recently received an approval notice from the National Medical Products Administration for the addition of a new specification of 10ml:1.5g for potassium chloride injection. The drug is used to treat and prevent hypokalemia, particularly in cases where oral potassium supplementation is not possible.

So far, Hubei TJ Pharma has invested approximately 5.57 million yuan in research and development costs for the potassium chloride injection project. According to data from Mianei Network, the domestic sales of potassium chloride injection were 612 million yuan and 661 million yuan in 2022 and 2023, respectively. The addition of the new specification and passing the consistency evaluation will help enrich medication options for patients, expand market share, and enhance market competitiveness. However, attention must also be paid to the potential impacts of policies and market conditions on drug development, production, and sales. In the first three quarters of 2024, TJ Pharma achieved revenue of 2.572 billion yuan and a net profit attributable to the parent company of 187 million yuan.

https://finance.eastmoney.com/a/202411253249775596.html